Literature DB >> 20081369

The Rad9A checkpoint protein is required for nuclear localization of the claspin adaptor protein.

Megan L Sierant1, Nicole E Archer, Scott K Davey.   

Abstract

The interaction between the 911 complex, via Rad9A, and Claspin is required for activation of the Chk1-mediated checkpoint response, along with ATR, TopBp1, and the 911 clamp loader complex Rad17/RFC. Despite the importance of the Rad9A-Claspin interaction in the cell cycle, this interaction has yet to be characterized. In this work we show this interaction persists in a variety of different conditions. During the course of this study we also determined the nuclear localization of Rad9A affected the localization of the Claspin protein, leading us to the conclusion that Rad9A is able to affect Claspin cellular localization. This was verified experimentally using a Rad9A-null cell line and reconstitution of Wt Rad9A. We also show that in meS cells the Rad9A paralog, Rad9B, is also capable of affecting Claspin localization. Together, these data suggest that Rad9 plays a role in locating Claspin to sites of DNA damage, facilitating its role during the Chk1-mediated checkpoint response. Since disruption of both Rad9A and Claspin has been shown to abolish Chk1 activation, we postulate that Rad9A-mediated Claspin localization is a vital step during checkpoint activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20081369     DOI: 10.4161/cc.9.3.10553

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  6 in total

Review 1.  p53 and RAD9, the DNA Damage Response, and Regulation of Transcription Networks.

Authors:  Howard B Lieberman; Sunil K Panigrahi; Kevin M Hopkins; Li Wang; Constantinos G Broustas
Journal:  Radiat Res       Date:  2017-01-31       Impact factor: 2.841

2.  Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition.

Authors:  Deborah A Greer Card; Megan L Sierant; Scott Davey
Journal:  J Biol Chem       Date:  2010-03-21       Impact factor: 5.157

3.  Prostate cancer: unmet clinical needs and RAD9 as a candidate biomarker for patient management.

Authors:  Howard B Lieberman; Alex J Rai; Richard A Friedman; Kevin M Hopkins; Constantinos G Broustas
Journal:  Transl Cancer Res       Date:  2018-01-14       Impact factor: 1.241

4.  Chk1 Activation Protects Rad9A from Degradation as Part of a Positive Feedback Loop during Checkpoint Signalling.

Authors:  William F Osorio-Zambrano; Scott Davey
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

5.  Loss of RAD9B impairs early neural development and contributes to the risk for human spina bifida.

Authors:  Xuanye Cao; Tian Tian; John W Steele; Robert M Cabrera; Vanessa Aguiar-Pulido; Shruti Wadhwa; Nikitha Bhavani; Patrick Bi; Nick H Gargurevich; Ethan N Hoffman; Chun-Quan Cai; Nicholas J Marini; Wei Yang; Gary M Shaw; Margaret E Ross; Richard H Finnell; Yunping Lei
Journal:  Hum Mutat       Date:  2020-01-16       Impact factor: 4.700

Review 6.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Richard A Franklin; Giuseppe Montalto; Melchiorre Cervello; Massimo Libra; Saverio Candido; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Ferdinando Nicoletti; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Francesca Chiarini; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.